SPFPL FAURE-PHARMA : revenue, balance sheet and financial ratios

SPFPL FAURE-PHARMA is a French company founded 18 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in NISSAN-LEZ-ENSERUNE (34440), this company of category PME shows in 2025 a revenue of 1.9 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SPFPL FAURE-PHARMA (SIREN 503357188)
Indicator 2025 2024 2023 2022 2021 2020 2019
Revenue 1 935 796 € N/C 2 608 557 € N/C N/C N/C N/C
Net income 61 393 € 133 133 € 52 144 € 69 436 € 62 732 € -36 589 € 58 672 €
EBITDA 89 601 € N/C 82 855 € N/C N/C N/C N/C
Net margin 3.2% N/C 2.0% N/C N/C N/C N/C

Revenue and income statement

In 2025, SPFPL FAURE-PHARMA achieves revenue of 1.9 M€. Revenue is declining over the period 2023-2025 (CAGR: -13.9%). After deducting consumption (1.4 M€), gross margin stands at 573 k€, i.e. a rate of 30%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 90 k€, representing 4.6% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 61 k€, i.e. 3.2% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2025) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

1 935 796 €

Gross margin (2025) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

572 883 €

EBITDA (2025) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

89 601 €

EBIT (2025) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

92 019 €

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

61 393 €

EBITDA margin (2025) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

4.6%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 10%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 79%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

10.01%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

78.65%

Cash flow / Revenue (2025) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

-69.404%

Repayment capacity (2025) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

-0.039

Solvency indicators evolution
SPFPL FAURE-PHARMA

Sector positioning

Debt ratio
10.01 2025
2023
2024
2025
Q1: 0.14
Med: 27.24
Q3: 146.28
Good -41 pts over 3 years

In 2025, the debt ratio of SPFPL FAURE-PHARMA (10.01) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
78.65% 2025
2023
2024
2025
Q1: 17.38%
Med: 54.75%
Q3: 87.41%
Good +43 pts over 3 years

In 2025, the financial autonomy of SPFPL FAURE-PHARMA (78.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
-0.04 years 2025
2023
2025
Q1: 0.0 years
Med: 0.77 years
Q3: 6.12 years
Excellent -50 pts over 2 years

In 2025, the repayment capacity of SPFPL FAURE-PHARMA (-0.04) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 756.37. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 19.1x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

756.374

Interest coverage (2025) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

19.115

Liquidity indicators evolution
SPFPL FAURE-PHARMA

Sector positioning

Liquidity ratio
756.37 2025
2023
2024
2025
Q1: 159.67
Med: 1116.63
Q3: 6512.12
Average +15 pts over 3 years

In 2025, the liquidity ratio of SPFPL FAURE-PHARMA (756.37) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
19.11x 2025
2023
2025
Q1: -191.54x
Med: -25.42x
Q3: 0.0x
Excellent

In 2025, the interest coverage of SPFPL FAURE-PHARMA (19.1x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 5 days. Favorable situation: supplier credit is longer than customer credit by 5 days. Overall, WCR represents 48 days of revenue, i.e. 258 k€ to permanently finance.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

258 313 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

5 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2025) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

48 j

WCR and payment terms evolution
SPFPL FAURE-PHARMA

Positioning of SPFPL FAURE-PHARMA in its sector

Comparison with sector Fonds de placement et entités financières similaires

Valuation estimate

Based on 170 transactions of similar company sales (all years), the value of SPFPL FAURE-PHARMA is estimated at 844 162 € (range 538 971€ - 1 216 871€). With an EBITDA of 89 601€, the sector multiple of 6.8x is applied. The price/revenue ratio is 0.71x (in line with sector norms). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
170 transactions
538k€ 844k€ 1216k€
844 162 € Range: 538 971€ - 1 216 871€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
89 601 € × 6.8x
Estimation 610 151 €
369 677€ - 1 075 328€
Revenue Multiple 30%
1 935 796 € × 0.71x
Estimation 1 372 658 €
917 440€ - 1 604 106€
Net Income Multiple 20%
61 393 € × 10.4x
Estimation 636 449 €
394 506€ - 989 879€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 170 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare SPFPL FAURE-PHARMA with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about SPFPL FAURE-PHARMA

What is the revenue of SPFPL FAURE-PHARMA ?

The revenue of SPFPL FAURE-PHARMA in 2025 is 1.9 M€.

Is SPFPL FAURE-PHARMA profitable?

Yes, SPFPL FAURE-PHARMA generated a net profit of 61 k€ in 2025.

Where is the headquarters of SPFPL FAURE-PHARMA ?

The headquarters of SPFPL FAURE-PHARMA is located in NISSAN-LEZ-ENSERUNE (34440), in the department Herault.

Where to find the tax return of SPFPL FAURE-PHARMA ?

The tax return of SPFPL FAURE-PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SPFPL FAURE-PHARMA operate?

SPFPL FAURE-PHARMA operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.